Leerink Partners reiterates Outperform on Cardinal Health stock By Investing.com

Cardinal Health raised FY2026 non-GAAP EPS guidance to at least $10.00 (from $9.65–$9.85) and the stock has returned 74% over the past year, trading at $219.40 with a $51.63B market cap. Multiple analysts bumped price targets after the guidance — Evercore to $260, Morgan Stanley to $245, TD Cowen to $233 — while Leerink reiterated an Outperform with a $275 target. Management highlighted strong specialty volumes, MSO M&A momentum, and opportunities in nuclear and diabetes supply businesses. Chief Accounting Officer Mary Scherer plans to retire in Feb 2027 with a successor search underway.

Analysis

Cardinal’s recent trajectory is less about a one-off beat and more about optionality compression across adjacent businesses — specialty distribution + MSO consolidation + niche supply (isotopes, diabetes consumables) create multiple, overlapping revenue compounding levers that can convert fixed-cost scale into outsized incremental margins over 12–36 months. That combination raises the value of stable contracting (re-contracting cycles) because each renewal now leverages cross-sell opportunities that raise lifetime customer revenue by more than headline distribution margins imply.

Second-order winners include private MSOs and specialty manufacturers that gain bargaining power and distribution economics from tighter ties to a large consolidator; second-order losers are standalone, smaller distributors and certain PBM-adjacent service providers that face deflationary pricing pressure if large distributors internalize services. Supply-side risks cluster around specialized inputs (medical isotopes, single-source diabetic consumables) where capacity shocks can swing quarterly margins and create short-term inventory-driven volatility.

Near-term catalysts are cadence of re-contracting wins, incremental M&A execution, and margin translation from specialty volumes; medium-term (6–24 months) risks are regulatory scrutiny on roll-ups, payer pushback on pricing, and integration slippage. Consensus appears to prize execution upside but underestimates the asymmetric payoff of niche-business optionality (nuclear/diabetes) — this makes a disciplined, time-boxed, option-levered approach preferable to a pure buy-and-hold exposure.

Key Decisions for Investors

• Long CAH equity (size 3–5% position): build into weakness over 4–8 weeks, target 12-month total return +20–30%, hard stop at -12% from entry to protect against integration/regulatory shocks.
• Buy CAH Jan 2028 LEAPS calls (~15% OTM): allocate 0.5–1% of portfolio to capture M&A and re-contract optionality with limited downside (premium), target asymmetric payoff 3:1 if specialty margins and MSO revenue accretion materialize within 18–30 months.
• Pair trade — long CAH / short MCK (1:0.8) for 6–12 months: capture relative execution on specialty/MSO vs hospital distribution exposure; expect 8–15% relative alpha if CAH converts cross-sell synergies, cut position if regulatory enforcement headlines surface.
• Event hedge: buy 3-month put spreads on CAH ahead of next major earnings/re-contracting update (cost ~0.3–0.7% of portfolio) to cap downside to ~10–15% for worst-case execution/macro surprise scenarios.